Michael W. Becker

This paper identifies the IL1β/IL1R1/IRAK4 axis as critical for inflammation-driven ovarian cancer metastasis and shows that IRAK4 inhibition with UR241-2 reduces tumor seeding and activates antitumor immune responses.

This study identifies CEBPD as a tumor suppressor gene in acute myeloid leukemia through functional experiments and genomic analyses.

This study identifies IL-1/IRAK1/4 signaling as a therapeutic target in AML stem cells, showing that UR241-2 inhibits LSC clonogenicity and engraftment in both diagnosis and relapse.

This study identifies PSP-0119, an IRAK4 degrader, as a promising therapy for FLT3-mutant AML by inhibiting IRAK4 activity and showing antileukemic effects in cell lines and xenograft models.

This study identifies the taurine-taurine transporter axis as a critical regulator of myeloid leukemia using temporal single-cell RNA-sequencing and functional experiments.

This paper develops a MIM model to study EOC metastasis at mesothelial injury sites and shows IRAK4 inhibitors reduce tumor burden more effectively than IL-1/IL-1R1 targeting agents.